SCHEMBL4071269

SCHEMBL4071269

C1=C(CN(Cc2ccccc2)c2ncnc3cc(-c4cccc(OCC5CC5)c4)sc23)OCO1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.36
STK17B O94768 3/20 0.34
IKBKB O14920 1/20 0.34
FFAR1 O14842 1/20 0.33
PPARD Q03181 1/20 0.33
EGFR P00533 2/20 0.32
MAP3K8 P41279 1/20 0.32
FLT1 P17948 3/20 0.32
SLC16A3 O15427 1/20 0.32
SLC16A1 P53985 1/20 0.32
MCTS1 Q9ULC4 1/20 0.32
CAMKK2 Q96RR4 1/20 0.31
ACHE P22303 1/20 0.31
LRRK2 Q5S007 1/20 0.31
SLC2A1 P11166 1/20 0.31
KIT P10721 1/20 0.31
HSD17B2 P37059 1/20 0.30
KDM5A P29375 1/20 0.30
KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930210 0.89 HSD17B2 (0.41) CSF1RSTK17BIKBKBEGFRMAP3K8
SCHEMBL4074723 0.87 IKBKB (0.40) STK17BIKBKBEGFRMAP3K8FLT1
SCHEMBL4069660 0.87 IKBKB (0.41) STK17BIKBKBEGFRMAP3K8FLT1
SCHEMBL4075052 0.85 MAP3K8 (0.45) CSF1RSTK17BIKBKBEGFRMAP3K8
SCHEMBL3933687 0.84 STK17B (0.44) STK17BIKBKBEGFRMAP3K8FLT1
SCHEMBL4068216 0.84 IKBKB (0.38) STK17BIKBKBEGFRMAP3K8FLT1
SCHEMBL4067150 0.84 RAB9A (0.45) CSF1RSTK17BIKBKBEGFRMAP3K8
SCHEMBL3924444 0.83 STK17B (0.35) STK17BIKBKBEGFRMAP3K8FLT1
SCHEMBL4076021 0.83 STK17B (0.38) STK17BIKBKBEGFRMAP3K8FLT1
SCHEMBL4068418 0.83 KIT (0.43) STK17BIKBKBEGFRMAP3K8FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 CSF1R 1260/4885STK17B 1911/4885IKBKB 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.